Skip to main content

MINI REVIEW article

Front. Med.
Sec. Nuclear Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1549676
This article is part of the Research Topic Pioneers & Pathfinders: 10 Years of Frontiers in Medicine View all 11 articles

An overview of current Phase 3 radiopharmaceutical therapy clinical trials

Provisionally accepted
Nicolas Lepareur Nicolas Lepareur 1,2*
  • 1 Centre Eugène Marquis, Rennes, France
  • 2 DĂ©partement de MĂ©decine NuclĂ©aire, Centre Eugène Marquis, Rennes, France

The final, formatted version of the article will be published soon.

    Over the past few years, radiopharmaceutical therapy has emerged as a groundbreaking therapeutic modality, taking advantage of the unique properties of radionuclides to deliver molecularly targeted therapy with high precision and transforming the landscape of precision oncology and personalized medicine. Its development reflects decades of advances in nuclear medicine, chemistry, and cancer biology. However, until recently, definitive clinical evidence was lacking to establish it into treatment plans, with few large randomized controlled clinical studies. The last two decades witnessed a paradigm shift, with three successful phase 3 studies which shed light on radiopharmaceutical therapy. This paper offers a brief overview of currently active phase 3 studies to highlight the dynamism and promise of this clinical domain, as well as the large variety of cancers being treated.

    Keywords: clinical trials, Nuclear Medicine, oncology, phase 3, Radiopharmaceutical therapy

    Received: 21 Dec 2024; Accepted: 04 Feb 2025.

    Copyright: © 2025 Lepareur. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Nicolas Lepareur, Centre Eugène Marquis, Rennes, France

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.